UNSPSC 51263107: Befunolol

This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C16H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 418546MT3A, chemically known as ketone, 7-(2-hydroxy-3-(isopropylamino)propoxy)-2-benzofuranyl methyl but generally known as befunolol, which bears US NIH Compound Identifier 2309. Befunolol most often comes in base and hydrochloride forms.

UNSPSC 51263107 Befunolol, a Commodity code, does not align with the recent state and local opportunities posted under this classification. The code nominally describes a specific pharmaceutical compound, yet the two recent solicitations tagged to it — Seminole County's procurement of naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs — involve naloxone supply, pharmacy benefit management infrastructure, and pharmaceutical distribution channels rather than befunolol specifically. State and local procurement offices appear to be using this code as a catch-all for pharmaceutical supply and pharmacy program work, despite the code's narrow nominal scope.

The issuing bodies include county health departments (Seminole County, Florida) and state health agencies (Texas HHS Commission). The single concrete solicitation with a response deadline is Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, closing July 26, 2023. The Texas RFI, posted April 3, 2026, with a response deadline of the same date, seeks vendor input on direct-to-manufacturer prescription fulfillment models but does not commit to a formal procurement timeline or award amount. Geographic activity is limited to Florida and Texas in recent records. Given the mismatch between the code's pharmaceutical-compound scope and the pharmacy-infrastructure and distribution work actually being solicited, this code shows little relevant recent activity for vendors in the befunolol market specifically.